| (19) |
 |
|
(11) |
EP 2 016 950 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
Note: Bibliography reflects the latest situation |
| (15) |
Correction information: |
|
Corrected version no 1 (W1 A1) |
| (48) |
Corrigendum issued on: |
|
01.07.2009 Bulletin 2009/27 |
| (43) |
Date of publication: |
|
21.01.2009 Bulletin 2009/04 |
| (22) |
Date of filing: 08.08.1997 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
| (30) |
Priority: |
08.08.1996 US 694954
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
97938261.1 / 0966297 |
| (71) |
Applicant: Amylin Pharmaceuticals, Inc. |
|
San Diego, CA 92121 (US) |
|
| (72) |
Inventors: |
|
- Young, Andrew A.
San Diego, CA 92121 (US)
- Gedulin, Bronislava
Del Mar, CA 92014 (US)
- Beely, Nigel Robert Arnold
Solana Beach, CA 92075 (US)
- Prickett, Kathryn S.
San Diego, CA 92126 (US)
|
| (74) |
Representative: Duckworth, Timothy John |
|
J.A. Kemp & Co.,
14 South Square,
Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB) |
|
| |
|
|
|
Remarks: |
|
This application was filed on 23-09-2008 as a divisional application to the application
mentioned under INID code 62. |
|
| (54) |
Pharmaceutical composition comprising an exendin-4 peptide |
(57) A pharmaceutical composition comprising an exendin-4 peptide comprising the amino
acid sequence HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS in an amount from 0.001 mg
to 1 mg based on a 70 kg patient; a pharmaceutically acceptable buffer; a pharmaceutically
acceptable isotonicity agent; and a pharmaceutically acceptable carrier.